HK Stock Market Move | HIGHTIDE-B(02511) rose over 13%, HTD1801 clinical trial results met expectations and plan to submit application for listing within the year.

HIGHTIDE-B(02511) rose by over 13%, up 11.16% as of press time, reaching 2.59 Hong Kong dollars, with a turnover of 9.641 million Hong Kong dollars. On the news front, JST Pharmaceuticals announced earlier that HTD1801 has achieved the primary endpoints in two Phase 3 clinical trials conducted in Chinese T2DM patients. The SYMPHONY 1 and SYMPHONY 2 trials showed significant improvements in HbA1c levels, fasting blood sugar, and lipid profile with HTD1801. JST Pharmaceuticals plans to submit a New Drug Application (NDA) to the National Medical Products Administration Drug Evaluation Center for the indication of T2DM treatment with HTD1801 within this year. Furthermore, JST Pharmaceuticals will present three research findings at the European Association for the Study of the Liver (EASL) 2025 meeting, including post-analysis results of a Phase 2 clinical study of berberine hydrochloride (HTD1801) for the treatment of metabolic-associated fatty liver disease (MAFLD), post-analysis results of a Phase 2 clinical study for the treatment of Type 2 diabetes (T2DM), and preclinical study results of Rimtoregtide (HTD4010) in liver failure mice.